Skip to main content
OpenTrials
Completed

NCT Number: NCT04615026

Prevalence of Thrombosis in COVID-Patients

Examination of the prevalence of thrombosis in COVID-patients, especially in an out-patient setting. Assessment by duplex sonography. If thrombosis is detected, we will correlate it with immunity status. Assessment of health issues and cognitive function as late complication after infection.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

University Hospital Augsburg

Augsburg, 86165, Germany

Who can participate

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • SARS CoV 2 positive swap, at least 4 weeks after infection

Exclusion criteria

  • under 18 years old no consent anemia

Treatment and study plan

duplex sonography

Diagnostic Test

all patients with consent receive a duplex ultrasound, blood test, cognitive test and test of smelling

Other names: test of smell, cognitive test, blood sample

Primary outcomes

  1. prevalence of thrombosis

    Time frame: 20 minutes

Secondary outcomes

  1. correlation to immunity

    Time frame: 20 minutes

  2. Assessment of late complications

    Time frame: 20 minutes

Sponsors and collaborators

Lead sponsor

University Hospital Augsburg

Other

Registry information

Official study title

Prevalence of Thrombosis in COVID-Patients in Correlation to Humoral and Cellular Immunity

Important dates

Study start
2020
Primary completion
2021
Study completion
2021
First posted
Nov 4, 2020
Registry last updated
Jun 2, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.